RNAseq data from myotubes after treatment with iAM373 in vitro

Sarcopenia represents an important health challenge with reduced quality of life and increased mortality. Gut microbiota have been suggested to contribute to this age-associated muscle wasting but the underlying mechanisms are still unclear. We uncovered the quorum sensing peptide iAM373 as a hitherto unknown contributor to sarcopenia. The involved pathways resulting in a decreased muscle metabolism were explored by RNA sequencing of C2C12 and human myotubes after treatment with iAM373 or placebo. Gene-set enrichment analysis (GSEA) with terms from Gene ontology (GO) biological processes, and KEGG, Biocarta and Reactome canonical pathways revealed an enrichment in gene sets involved in striated muscle development and differentiation in iAM373 treated samples. Most of these gene sets were downregulated by iAM373. The proteasome degradation pathway was also enriched, i.e., upregulated in murine and human myotubes after QSP incubation. Murine (C2C12) or human (AB678C53Q) myotubes were treated with quorum sensing peptide iAM373 or placebo for 8 hours or 24 hours in vitro. RNA sequencing was conducted for pathway analysis. N=10 for each condition at specific timepoint (N=40 in total)